title: Point: should fibrinolytics be routinely administered intrapleurally for management of a complicated parapneumonic effusion? Yes.
authors.affiliation: Oxford Centre for Respiratory Medicine, Oxford University Hospitals, Oxford, England; Oxford Respiratory Trials Unit, University of Oxford, Oxford, England.
authors.forename: John P
authors.initials: JP
authors.lastname: Corcoran
authors.affiliation: Oxford Centre for Respiratory Medicine, Oxford University Hospitals, Oxford, England; Oxford Respiratory Trials Unit, University of Oxford, Oxford, England; NIHR Oxford Biomedical Research Centre, Oxford, England. Electronic address: najib.rahman@ndm.ox.ac.uk.
authors.forename: Najib M
authors.initials: NM
authors.lastname: Rahman
mesh_terms: D000287:Administration, Topical; D004322:Drainage / Q000379:methods*; D016724:Empyema, Pleural / Q000628:therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D010996:Pleural Effusion / Q000628:therapy*; D013300:Streptokinase / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator